In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…
Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
A study of nintedanib in patients with ILD associated with systemic sclerosis showed the treatment had only limited improvement. Although these patients had a lower rate of decline in forced vital capacity than those on placebo, nintedanib did not result in clinical benefits for other manifestations of systemic sclerosis…
Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
Adding certolizumab pegol to background medication is better than adding a placebo for patients with active nonradiographic axial spondyloarthritis, according to a new study…
The Rescue: Moving RA Patients from Adalimumab to Baricitinib
The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…
Scientist Development Award Winner Probes Ethnic Disparities in Lupus
Recipient of a Rheumatology Research Foundation Scientist Development Award, Ashira Blazer, MD, focuses her research on racial and ethnic disparities in lupus. She looks beyond socioeconomic differences, differences in lifestyles and access to care to better understand the biologically determined differences behind disparate outcomes. With funding from the Foundation, she was able to investigate the…
Advanced Practice Providers Should Learn Musculoskeletal Ultrasound
I have worked as an advanced practice provider (APP) in pediatric rheumatology for nearly 16 years. My collaborating physicians have allowed me to function to the full extent of my scope of practice while allowing me to develop professionally within the subspecialty. My latest endeavor has been learning how to perform musculoskeletal ultrasound (MSUS) and…
A New Treatment for Axial Spondyloarthritis?
If approved by the U.S. Food and Drug Administration (FDA), difficult-to-treat patients with axial spondyloarthritis who fail or are intolerant to standard treatment with tumor necrosis factor inhibitors (TNFi) may have a new treatment option. That new option is a high-affinity monoclonal antibody, called ixekizumab, which selectively targets an area linked to the immunopathology of…
Genomics Research Highlighted at Lupus Conference
SAN FRANCISCO—The challenges of trying to solve the puzzle of lupus, in light of its broad heterogeneity of symptoms, manifestations in clinical involvement and treatment response, and the sheer complexities of the immune system, are driving researchers into ever more elaborate investigations of how the immune system functions in lupus patients. Genetic, transcriptomic and epigenetic…
Research Advances Continue in the Fight Against Lupus
SAN FRANCISCO—The 13th International Congress on Systemic Lupus Erythematosus (SLE), held April 5–8, highlighted continuing advances in the fight against lupus, a chronic, inflammatory, autoimmune disease affecting multiple organ systems. The rheumatologist’s ability to control this incurable and life-threatening condition is limited both by its heterogeneous presentation and by the lack of successful treatment options,…
Researchers Examine Lupus Patient Data for Disease Activity Predictors
A recent analysis of retrospective clinical data on patients with systemic lupus erythematosus (SLE) at 14 Canadian centers found that a surprisingly high proportion—at least one-third—had active disease at any point over five years of data collection.1 It has been a longstanding belief among clinicians that SLE becomes less active over time, although its accumulation…
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 337
- Next Page »